September 16, 2013 Pending High Profile Biotech IPO Should Raise Nuvilex’s ValuationThere is a buzz in certain biotech circles regarding the high value of encapsulation technologies and targeted therapy delivery platforms. Firms that have exposure to, or are major participants in these segments are just now beginning to garner significant interest from larger players, thus enabling them to enjoy increasingly favorable valuations. For example, Bind Therapeutics, Inc., a high profile biotech that recently filed to go public via an Initial Public Offering through leading health care investment banks, is one of these companies. Considering the striking similarities between Bind and Nuvilex, Inc. (OTCQB – NVLX - $0.15 – Spec Buy), Nuvilex’s shares could enjoy a big boost once Bind’s IPO registration becomes effective. Bind is developing a therapy using what it terms Accurins. Accurins are polymeric nanoparticles that incorporate a therapeutic payload and are designed to have prolonged circulation within the bloodstream, enable targeting of the diseased tissue or cells, and provide for the controlled and timely release of the therapeutic payload at the site of disease to enhance efficacy while minimizing adverse effects on healthy tissues. Bind’s nanomedicine platform for developing targeted therapies to treat forms of cancer has caught the eye of big pharma. The Company, which has two Phase II cancer clinical trials in progress, has already received $13M in milestone payments. To date, Bind has announced collaborations with Amgen, Pfizer and AstraZeneca to develop Accurins based on therapeutic payloads from their product pipelines, with the potential to achieve a total of over $1 billion in upfront and future milestone payments, including over $450 million in pre-commercial milestones. If the description of the Bind Therapeutics approach sounds familiar to Nuvilex investors, it should. Both companies are engaged in developing a platform approach to targeted therapies using a prodrug to treat the targeted cancerous tissues and cells directly at the site with fewer side effects than traditional treatments. Both firms’ technology could potentially be used in conjunction with currently approved drugs for the treatment of many different forms of cancer by optimizing the anticancer activity of such drugs. As evidenced by the development deals with big pharma, Bind Therapeutics may be ahead of Nuvilex for the time-being but we believe that Nuvilex’s stock trading pattern will closely mirror that of Bind’s and that the Company will greatly benefit from Bind’s likely high valuation as a consequence of the latter’s IPO.For more information, refer to our previous NVLX Reports, Updates and Hot Topics by visiting www.GoldmanResearch.com
You Might Also Like
Senior Analyst: Robert Goldman Analyst Certification Disclaimer Goldman Small Cap Research is not affiliated in any way with Goldman Sachs & Co. The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research did not make an independent investigation or inquiry as to the accuracy of any information provided by the Company, or other firms. Goldman Small Cap Research relied solely upon information provided by the Company through its filings, press releases, presentations, and through its own internal due diligence for accuracy and completeness. Such information and the opinions expressed are subject to change without notice. A Goldman Small Cap Research report, update, article, or note is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. This publication does not take into account the investment objectives, financial situation, or particular needs of any particular person. This report does not provide all information material to an investor’s decision about whether or not to make any investment. Any discussion of risks in this presentation is not a disclosure of all risks or a complete discussion of the risks mentioned. Neither Goldman Small Cap Research, nor its parent, is registered as a securities broker-dealer or an investment adviser with FINRA, the U.S. Securities and Exchange Commission or with any state securities regulatory authority. ALL INFORMATION IN THIS REPORT IS PROVIDED “AS IS” WITHOUT WARRANTIES, EXPRESSED OR IMPLIED, OR REPRESENTATIONS OF ANY KIND. TO THE FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE FOR THE QUALITY, ACCURACY, COMPLETENESS, RELIABILITY OR TIMELINESS OF THIS INFORMATION, OR FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES THAT MAY ARISE OUT OF THE USE OF THIS INFORMATION BY YOU OR ANYONE ELSE (INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, LOSS OF OPPORTUNITIES, TRADING LOSSES, AND DAMAGES THAT MAY RESULT FROM ANY INACCURACY OR INCOMPLETENESS OF THIS INFORMATION). TO THE FULLEST EXTENT PERMITTED BY LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE TO YOU OR ANYONE ELSE UNDER ANY TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY, PRODUCTS LIABILITY, OR OTHER THEORY WITH RESPECT TO THIS PRESENTATION OF INFORMATION. For more information, visit our Disclaimer: www.goldmanresearch.com |